JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

Search

MannKind Corp

Cerrado

SectorSanidad

3.51 2.93

Resumen

Variación precio

24h

Actual

Mínimo

3.51

Máximo

3.54

Métricas clave

By Trading Economics

Ingresos

5.7M

13M

Ventas

1.6M

78M

P/B

Media del Sector

39.2

34.393

Margen de beneficios

16.793

Empleados

403

EBITDA

8.3M

27M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+163.92% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-316M

1.2B

Apertura anterior

0.58

Cierre anterior

3.51

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

21 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

MannKind Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 ago 2025, 21:43 UTC

Ganancias

Constellation Software 2Q Revenue Rises, Profit Shrinks

8 ago 2025, 16:39 UTC

Adquisiciones, fusiones, absorciones

Vinci Faces Reduced Earnout Payments to ACS for Cobra IS Deal

8 ago 2025, 22:42 UTC

Adquisiciones, fusiones, absorciones

The Paramount Merger Was a Bad Deal for Old Shareholders. Buying the Stock Is a Good Bet for New Ones. -- Barrons.com

8 ago 2025, 21:31 UTC

Charlas de Mercado
Ganancias

Cautious Long-Term Outlook For Natural Diamond Prices -- Market Talk

8 ago 2025, 21:00 UTC

Ganancias

Constellation Software 2Q Rev $2.84B >CSU.T

8 ago 2025, 21:00 UTC

Ganancias

Constellation Software 2Q Net $56M >CSU.T

8 ago 2025, 21:00 UTC

Ganancias

Constellation Software 2Q EPS $2.66 >CSU.T

8 ago 2025, 20:55 UTC

Charlas de Mercado

Ahead of Cisco's Earnings, Investors Should Expect Conservatism -- Market Talk

8 ago 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

8 ago 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 ago 2025, 20:35 UTC

Charlas de Mercado

Mexico's Industrial Production Seen Higher in June -- Market Talk

8 ago 2025, 20:28 UTC

Ganancias

MP Materials Stock Soars Even Higher on Earnings. The Future Looks Bright, Too. -- Barrons.com

8 ago 2025, 20:28 UTC

Ganancias

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 ago 2025, 20:20 UTC

Adquisiciones, fusiones, absorciones

Boeing's Spirit AeroSystems Deal Gets U.K. Approval. It's Part of the Turnaround. -- Barrons.com

8 ago 2025, 20:08 UTC

Ganancias

Tredegar: Recent Decline in Orders, Which Is a Measure of Future Sales Volume, Is Due to Lower Demand for Aluminum Extrusions in U.S. and Customers Pausing Orders to Evaluate New Higher Tariff >TG

8 ago 2025, 19:34 UTC

Charlas de Mercado

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 ago 2025, 19:15 UTC

Charlas de Mercado

U.S. Natural Gas Futures Settle Under $3 -- Market Talk

8 ago 2025, 19:13 UTC

Charlas de Mercado

Oil Futures End Volatile Week Lower -- Market Talk

8 ago 2025, 18:21 UTC

Charlas de Mercado

Gold Gains for the Week as Tariffs Go Forward -- Market Talk

8 ago 2025, 17:27 UTC

Ganancias

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 ago 2025, 17:09 UTC

Ganancias

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 ago 2025, 17:03 UTC

Ganancias

Pinterest Stock Gets Multiple Price Target Hikes. Shares Tumble on Earnings Miss. -- Barrons.com

8 ago 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

8 ago 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

8 ago 2025, 15:53 UTC

Adquisiciones, fusiones, absorciones

Vinci: New Provisions Will Have No Significant Impact on Vinci's Financial Statements

8 ago 2025, 15:51 UTC

Adquisiciones, fusiones, absorciones

Vinci, ACS Terminate Agreement Regarding Creation of Joint Venture in Renewable Energy

8 ago 2025, 15:50 UTC

Adquisiciones, fusiones, absorciones

Vinci to Pay EUR300M of That Sum to ACS Taking Into Account Payments Already Made

8 ago 2025, 15:48 UTC

Adquisiciones, fusiones, absorciones

Vinci, ACS Agreed to Fix Earn-Out Related to Cobra IS Developments in Renewable Energy at EUR380M Payable in Cash

8 ago 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Vinci: Acquisition of Cobra IS Was Completed Dec. 31, 2021

8 ago 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Vinci: Agreement Will Definitively Settle Certain Provisions Related to Acquisition of Cobra IS

Comparación entre iguales

Cambio de precio

MannKind Corp previsión

Precio Objetivo

By TipRanks

163.92% repunte

Estimación a 12 Meses

Media 9.29 USD  163.92%

Máximo 12 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MannKind Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.079 / 4.323Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

21 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.